


## Colestilan

<b>Cat. No.:</b>	HY-112939
<b>CAS No.:</b>	95522-45-5
<b>Molecular Formula:</b>	(C <sub>4</sub> H <sub>6</sub> N <sub>2</sub> ·C <sub>3</sub> H <sub>5</sub> ClO) <sub>x</sub>
<b>Target:</b>	Others
<b>Pathway:</b>	Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Colestilan (MCI-196) is a non-absorbed, non-calcium-based phosphate binder and is also a non-metallic, anion exchange resin. Colestilan is orally active and can be used for hypercholesterolaemia research <sup>[1][2]</sup> .									
<b>In Vitro</b>	Colestilan (MCI-196) decreases cholesterol levels by bile acid adsorption through the gastrointestinal tract <sup>[2]</sup> . Colestilan (1 g) binds 2.52 mmol of phosphate at 2–4 mM phosphate concentration and pH7.2 in vitro <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.									
<b>In Vivo</b>	<p>Colestilan (MCI-196) (0.125 or 0.5 g content per 15 g of the feed; p.o.; 14 days) decreases blood phosphate and urinary phosphorus excretion in rats<sup>[3]</sup>.</p> <p>Colestilan is able to improve hyperphosphataemia in rats with renal failure induced by adenine administration for 4 weeks<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>6-week old Wistar male rats<sup>[3]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0.125 or 0.5 g content per 15 g of the feed</td> </tr> <tr> <td>Administration:</td> <td>Oral in feed, 14 days</td> </tr> <tr> <td>Result:</td> <td>Dose dependently decreased blood phosphate and urinary phosphate excretion.</td> </tr> </table>		Animal Model:	6-week old Wistar male rats <sup>[3]</sup>	Dosage:	0.125 or 0.5 g content per 15 g of the feed	Administration:	Oral in feed, 14 days	Result:	Dose dependently decreased blood phosphate and urinary phosphate excretion.
Animal Model:	6-week old Wistar male rats <sup>[3]</sup>									
Dosage:	0.125 or 0.5 g content per 15 g of the feed									
Administration:	Oral in feed, 14 days									
Result:	Dose dependently decreased blood phosphate and urinary phosphate excretion.									

### REFERENCES

- [1]. Locatelli F, et al. Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. *Nephrol Dial Transplant*. 2010 Feb;25(2):574-81.
- [2]. Kurihara S, et al. Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in aemodialysis patients: a double-blind, placebo-controlled, short-term trial. *Nephrol Dial Transplant*. 2005 Feb;20(2):424-30.
- [3]. MATSUKA MASAYUKI, et al. Use of anion exchange resins for the manufacture of a medicament for the treatment of hyperphosphatemia. Patent EP0793960.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA